Author(s)

Lianfang Xue^1,#, Hui Liu^1,#, Suishan Qiu¹, Qinai Zhu², Shasha Li¹, Liang Ding^3,*, Congxiu Ye^4,**

Affiliation(s)

¹Department of Pharmacy, The First Affiliated Hospital of Jinan University, Guangzhou 510630, China

²Department of Laboratory Medicine, The First Affiliated Hospital of Jinan University Guangzhou 510630, China

³Clinical Trial and Research Center, People's Hospital of Shenzhen Baoan District, Shenzhen, 518101, China

⁴Department of Dermatology and Venerology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China

Corresponding Author

Liang Ding, Congxiu Ye

ABSTRACT

Escherichia coli (E. coli) is one of the most common causes of hospital-acquired infection. Our aim was to assess the evolution of Imipenem Resistance in Escherichia coli at the First Affiliated Hospital of Jinan University (Guangzhou, China) from 2010 to 2018. 3412 non-duplicate strains of E. coli were isolated from inpatients and outpatients during the researched period. The majority of isolates appeared in the urine sample (57.68%) were derived from Urology(33.76%). With an average imipenem resistance rate of 0.61%, 27 strains of E. coli were detected. From 2010 to 2018, the resistance rates of the 3412 strains of E. coli to imipenem were 0, 0.00%, 0.35%, 0.30%, 0.26%, 0.44%, 1.08%, 0.70%, 2.33%, respectively. The overall imipenem resistant rate of E. coli was gradually increased in recent years. Moreover, the imipenem-resistant E. coli was multi-drug resistant to the antibiotics used clinically.. Therefore, restraining the use of antibiotics is extremely urgent to avoid severe infection by resistant pathogens.

KEYWORDS

Escherichia coli; Imipenem; Antibiotic resistance

CITE THIS PAPER

Lianfang Xue, Hui Liu, Suishan Qiu, Qinai Zhu, Shasha Li, Liang Ding, Congxiu Ye. Evolution of imipenem resistance in escherichia coli: a 9-year retrospective surveillance report in a hospital population of southern China. Acta Translational Medicine. 2021, 4(1): 1-9.

REFERENCES

1. Kaper JB, Nataro JP, and Mobley HLT. Pathogenic Escherichia coli. Nat Rev Microbiol. 2004; 2:123-140.

2. Alabsi MS, Ghazal A, Sabry SA, and Alasaly MM. Association of some virulence genes with antibiotic resistance among uropathogenic Escherichia coli isolated from urinary tract infection patients in Alexandria, Egypt: A hospital-based study. Journal of Global Antimicrobial Resistance. 2014;2:83-86.

3. Codjoe, F. S., Donkor, E. S. Carbapenem Resistance: A Review. Med Sci. 2017;(Basel). 6.

4. Magiorakos, A. P., Burns, K., Roiguez Bano, J., Borg, M., Daikos, G., Dumpis, U., Voss, A., and Weber, J. T. Infection prevention and control measures and tools for the prevention of entry of carbapenem-resistant Enterobacteriaceae into healthcare settings: guidance from the European Centre for Disease Prevention and Control. Antimicrobial Resistance and Infection Control. 2017;6:113-117.

5. Shaowei Zheng, Ping Li, Zhengliang Zhang, and Honghong Fei. Surveillance of carbapenem antibiotic resistance of common gram-negative bacteria in CHINET in China from 2005 to 2017. Journal of Clinical Emergency. 2019;20:45-49.

6. Karaiskos I, Giamarellou H. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother. 2014;15: 1351-1370.

7. Yamachika, S., Sugihara, C., Kamai, Y., and Yamashita, M. Correlation between penicillin-binding protein 2 mutations and carbapenem resistance in Escherichia coli. Journal of Medical Microbiology. 2013;62:429.

8. Wozniak, A., Villagra, N. A., Undabarrena, A., Gallardo, N., Keller, N., Moraga, M., Román, J. C., Mora, G. C., and García, P. Porin alterations present in non-carbapenemase-producing Enterobacteriaceae with high and intermediate levels of carbapenem resistance in Chile. Journal of Medical Microbiology. 2012;61:1270-1279.

9. Skalweit MJ, Li M. Bulgecin A as a β-lactam enhancer for carbapenem-resistant Pseudomonas aeruginosa and carbapenem-resistant Acinetobacter baumannii clinical isolates containing various resistance mechanisms. Drug Design, Development and Therapy. 2016;10:3013-3020.

10. Grundmann, H., Glasner, C., Albiger, B., Aanensen, D. M., Tomlinson, C. T., Andrasevic, A. T., Cantón, R., Carmeli, Y., Friedrich, A. W., Giske, C. G., Glupczynski, Y., Gniadkowski, M., Livermore, D. M., Nordmann, P., Poirel, L., Rossolini, G. M., Seifert, H., Vatopoulos, A., Walsh, T., Woodford, N., Monnet, D. L., Koraqi, A., Lacej, D., Apfalter, P., Hartl, R., Glupczynski, Y., Huang, T., Strateva, T., Marteva-Proevska, Y., Andrasevic, A. T., Butic, I., Pieridou-Bagatzouni, D., Maikanti-Charalampous, P., Hrabak, J., Zemlickova, H., Hammerum, A., Jakobsen, L., Ivanova, M., Pavelkovich, A., Jalava, J., Osterblad, M., Dortet, L., Vaux, S., Kaase, M., Gatermann, S. G., Vatopoulos, A., Tryfinopoulou, K., Tóth, á., Jánvári, L., Boo, T. W., McGrath, E., Carmeli, Y., Adler, A., Pantosti, A., Monaco, M., Raka, L., Kurti, A., Balode, A., Saule, M., Miciuleviciene, J., Mierauskaite, A., Perrin-Weniger, M., Reichert, P., Nestorova, N., Debattista, S., Mijovic, G., Lopicic, M., Samuelsen, O., Haldorsen, B., Zabicka, D., Literacka, E., Canica, M., Manageiro, V., Kaftandzieva, A., Trajkovska-Dokic, E., Damian, M., Lixandru, B., Jelesic, Z., Trudic, A., Niks, M., Schreterova, E., Pirs, M., Cerar, T., Oteo, J., Aracil, B., Giske, C., Sjostrom, K., Gür, D., Cakar, A., Woodford, N., Hopkins, K., Wiuff, C., and Brown, D. J. Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. The Lancet Infectious Diseases 2017;17:153-163.

11. Kazi, M., Drego, L., Nikam, C., Ajbani, K., Soman, R., Shetty, A., and Rodrigues, C. 2015. Molecular characterization of carbapenem-resistant Enterobacteriaceae at a tertiary care laboratory in Mumbai. European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology 2015;34: 467-472.

12. Yin Danping, Zhou Guoqing. Study on the clinical distribution and drug resistance of carbapenem resistant Enterobacteriaceae. Chinese Journal of Nosocomial Infection 2018;28: 2752-2755.

13. Zilberberg MD, Shorr AF. Prevalence of multidrug-resistant Pseudomonas aeruginosa and carbapenem-resistant Enterobacteriaceae among specimens from hospitalized patients with pneumonia and bloodstream infections in the United States from 2000 to 2009. J Hosp Med 2013; 8: 559-563.

14. Xu, Z., Li, L., Shirtliff, M. E., Peters, B. M., Peng, Y., Alam, M. J., Yamasaki, S., and Shi, L. 2010. First report of class 2 integron in clinical Enterococcus faecalis and class 1 integron in Enterococcus faecium in South China. Diagnostic Microbiology and Infectious Disease 2010; 68: 315-317.

15. Xie J, Peters BM, Li B, Li L, Yu G, Xu Z, and Shirtliff ME. Clinical features and antimicrobial resistance profiles of important Enterobacteriaceae pathogens in Guangzhou representative of Southern China, 2001-2015. Microbial Pathogenesis 2017; 107: 206-211.

16. van Duin D, Kaye KS, Neuner EA, and Bonomo RA. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagnostic Microbiology & Infectious Disease 2013; 75: 115-120.

17. Fupin Hu, Demei Zhu, Fu Wang, Xiaofei Jiang, Qing Yang, Yingchun Xu, Xiaojiang Zhang, Ziyong Sun, Zhongju Chen, Chuanqing Wang, Aimin Wang, Yuxing Ni, Jingyong Sun, Yunsong Yu, Jie Lin, Bin Shan, Yan Du, Yuanhong Xu, Jilu Shen, Hong Zhang, Jing Kong, Chao Zhou, Danhong Su, Zhaoxia Zhang, Ping Ji, Yunjian Hu, Xiaoman Ai, Wenxiang Huang, Bei Jia, Lianhua Wei, and Ling Wu. 2017 China bacterial resistance monitoring. China Journal of Infection and Chemotherapy 2018; 18: 241-251.

18. Luo Ling, Liu Xiaoqiang, Ou Yangying, et al. Drug resistance analysis of 1411 strains of Escherichia coli. Chinese Journal of Health Inspection 2012; 22: 1706-1707.

19. Ke Zhao, Pengcheng Xia, Zhijun Zhang, and Shuping Zhao. Clinical distribution and drug resistance analysis of 4828 strains of Escherichia coli. International Journal of Laboratory Medicine 2018; 39: 1765-1768.

20. Zhang, R., Liu, L., Zhou, H., Chan, E. W., Li, J., Fang, Y., Li, Y., Liao, K., and Chen, S. Nationwide Surveillance of Clinical Carbapenem-resistant Enterobacteriaceae (CRE) Strains in China. EBioMedicine 2017; 19: 98-106.

21. Toner, L., Papa, N., Aliyu, S. H., Dev, H., Lawrentschuk, N., and Al-Hayek, S. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospital urinary tract infections: incidence and antibiotic susceptibility profile over 9 years. World J Urol 2016; 34: 1031-1037.

22. Wang, Q., Zhang, Y., Yao, X., Xian, H., Liu, Y., Li, H., Chen, H., Wang, X., Wang, R., Zhao, C., Cao, B., and Wang, H. Risk factors and clinical outcomes for carbapenem-resistant Enterobacteriaceae nosocomial infections. Eur J Clin Microbiol Infect Dis 2016; 35: 1679-1689.

23. Pannaraj, P. S., Bard, J. D., Cerini, C., and Weissman, S. J. Pediatric carbapenem-resistant Enterobacteriaceae in Los Angeles, California, a high-prevalence region in the United States. The Pediatric Infectious Disease Journal 2015; 34: 11-16.

24. Cai, J. C., Zhang, R., Hu, Y. Y., Zhou, H. W., and Chen, G. X. Emergence of Escherichia coli sequence type 131 isolates producing KPC-2 carbapenemase in China. Antimicrob Agents Chemother 2014; 58: 1146-1152.

25. Yang, Q., Fang, L., Fu, Y., Du, X., Shen, Y., and Yu, Y. Dissemination of NDM-1-Producing Enterobacteriaceae Mediated by the IncX3-Type Plasmid. PLoS One 2015; 10: e129454.

26. Qu, H., Wang, X., Ni, Y., Liu, J., Tan, R., Huang, J., Li, L., and Sun, J. NDM-1-producing Enterobacteriaceae in a teaching hospital in Shanghai, China: IncX3-type plasmids may contribute to the dissemination of blaNDM-1. International Journal of Infectious Diseases 2015; 34: 8-13.

27. Smith K.P., Kirby J E. Evaluation of apramycin activity against carbapenem-resistant and susceptible strains of Enterobacteriaceae. Diagnostic Microbiology and Infectious Disease 2016; 86: 439-441.